Anbio BiotechnologyNNNN -4.13%24 PE Ratio (TTM) is 78.16 as of Jul. 08, 2026, which is 58% below its 10-year median of 184.69. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 435 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 87.59% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-08), Anbio Biotechnology's share price is
$11.49.
Anbio Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15. Therefore, Anbio Biotechnology's PE Ratio (TTM) for today is 78.16.
Good Sign:
Anbio Biotechnology stock PE Ratio (=81.53) is close to 2-year low of 81.53.
The historical rank and industry rank for Anbio Biotechnology's PE Ratio (TTM) or its related term are showing as below:
NNNN'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 74.49 Med: 184.69 Max: 945.56
Current: 78.16
During the past 5 years, the highest PE Ratio (TTM) of Anbio Biotechnology was 945.56. The lowest was 74.49. And the median was 184.69.
NNNN's PE Ratio (TTM) is ranked worse than 87.59% of 435
companies
in the Medical Devices & Instruments industry
Industry Median: 26.6
vs NNNN: 78.16
During the past 5 years, Anbio Biotechnology's highest 3-Year average EPS without NRI Growth Rate was 29.30% per year. The lowest was 24.20% per year. And the median was 26.75% per year.
Anbio Biotechnology's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.06.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.
Anbio Biotechnology (NAS:NNNN) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Anbio Biotechnology PE Ratio (TTM) Related Terms
Anbio Biotechnology PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: PE Ratio (TTM) Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology PE Ratio (TTM) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Anbio Biotechnology's Share Price of today is $11.49.
For company reported semi-annually, Anbio Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Anbio Biotechnology (NNNN) has a PE Ratio (TTM) of 78.16 as of Jul. 08, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Anbio Biotechnology and its competitors. This is 58% below median its historical median of 184.69. Over the past decade, Anbio Biotechnology's PE Ratio (TTM) has ranged from 74.49 to 945.56. According to the industry distribution chart, Anbio Biotechnology ranks #381 out of 435 companies in the Medical Devices & Instruments industry, placing it in the top 87.6%.
Is Anbio Biotechnology's PE Ratio (TTM) too high?
Anbio Biotechnology's current PE Ratio (TTM) of 78.16 is 58% below median its 10-year median of 184.69. Over the past 10 years, this metric has ranged from a low of 74.49 to a high of 945.56. The Medical Devices & Instruments industry median PE Ratio (TTM) is 26.60. Anbio Biotechnology's value of 78.16 is 193.8% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #381 out of 435 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's PE Ratio (TTM) compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #381 out of 435 companies for PE Ratio (TTM). This places Anbio Biotechnology in the lower half of its industry. The industry median PE Ratio (TTM) is 26.60. Anbio Biotechnology's value of 78.16 is 193.8% above this benchmark. Historically, Anbio Biotechnology's own PE Ratio (TTM) has ranged from 74.49 to 945.56 over the past decade. While the company's 10-year median is 184.69 vs. the industry median of 26.60, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Devices & Instruments company?
The median PE Ratio (TTM) among Medical Devices & Instruments companies is 26.60, based on 435 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current PE Ratio (TTM) of 78.16 is 193.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio (TTM) is 26.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current PE Ratio (TTM) is 78.16, which is 58% below median its own 10-year median of 184.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current PE Ratio (TTM) of 78.16. The current PE Ratio (TTM) is 78.16, which is 58% below median its 10-year median of 184.69 and 193.8% above the Medical Devices & Instruments industry median of 26.60. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current PE Ratio (TTM) is 78.16 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
